Organon & Co. — Form 10-Q Summary
Business context and reporting period
Global healthcare company focused on women’s health, biosimilars and established brands, with more than 60 medicines and products. This unaudited report covers the quarter and nine months ended September 30, 2022, compared with the corresponding 2021 periods. Organon completed its separation from Merck in June 2021; pre-separation comparisons include certain Merck-derived allocations and may not represent standalone costs.
Key financial metrics
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $1.537 billion | $1.600 billion | $4.689 billion | $4.701 billion |
| Net income | $227 million | $323 million | $809 million | $1.149 billion |
| Diluted EPS | $0.89 | $1.27 | $3.17 | $4.52 |
| Gross margin | 64% | 62% | 64% | 62% |
| Operating cash flow | Not provided for quarter | Not provided for quarter | $591 million | $2.113 billion |
Revenue was down 4% in Q3, primarily reflecting $106 million of unfavorable foreign exchange and timing of tenders in Brazil; excluding foreign exchange, revenue increased 3%. Nine-month revenue was nearly unchanged, but increased 5% excluding foreign exchange. Q3 and nine-month net income each declined about 30% year over year.
For the nine months, cost of sales declined 5% to $1.700 billion, while SG&A rose 4% to $1.234 billion and R&D increased 44% to $329 million. Interest expense rose to $303 million from $160 million. The 2021 comparison benefited from a $70 million tax benefit and other tax-related benefits; the effective tax rate was 20.0% in 2022 versus 11.2% in 2021 for the nine-month period.
At September 30, cash and cash equivalents were $499 million, versus $737 million at year-end 2021. Current assets were $3.592 billion and current liabilities $2.328 billion; reported working capital was $1.3 billion. Long-term debt principal was $8.699 billion, with $8.691 billion reported as long-term debt net of current portion. No revolving-credit borrowings were outstanding; the company reported compliance with its financial covenants. The weighted-average borrowing rate was 4.5%.
Material changes and business developments
- Q3 international revenue fell 7% as reported but rose 2% excluding foreign exchange; U.S. revenue increased 6%. Nine-month international revenue declined 1% as reported and grew 6% excluding foreign exchange.
- Nexplanon/Implanon NXT sales rose 31% in Q3 and 10% for nine months. Renflexis sales increased 11% and 22%, respectively. NuvaRing nine-month sales fell 10%, mainly due to U.S. generic competition; management expects further decline.
- Operating cash flow fell to $591 million from $2.113 billion, primarily due to lower trade payables, including balances with Merck. Cash used in investing was $359 million, including spending on product rights and licensing; cash used in financing was $351 million, including dividends.
- Organon paid $100 million to prepay its U.S.-dollar term loan in June. It declared a quarterly dividend of $0.28 per share, payable December 15, 2022.
Outlook, risks and unusual items
The filing provides no specific quantitative revenue or earnings guidance. Management expects positive operating cash flow and says cash, operating cash generation, revolving-credit availability and capital-market access should fund anticipated needs. It expects volume-based procurement to affect established brands in coming quarters and expects generic competition to continue reducing NuvaRing sales.
Management cited ongoing COVID-19 effects, including reduced healthcare access and lockdowns in selected Chinese cities, as sources of potential short-term volatility. Other risks include foreign-exchange movements, pricing and generic competition, supply and third-party dependencies, and the Russia-Ukraine conflict; Russia and Ukraine together represented about 2% of revenue. Variable-rate debt exposes interest expense to rate changes, and the company has no interest-rate derivatives. The company said risk factors had not materially changed from its 2021 Form 10-K.
Business-development commitments include up to $360 million in potential Cirqle milestones, up to $468 million for Henlius and up to $182.5 million for Daré, plus potential royalties where applicable. These are contingent payments, not amounts currently recorded as liabilities. A $9 million biosimilar product-right impairment and $11 million of restructuring costs were recorded during the nine months. The Inflation Reduction Act had no Q3 impact; future effects were still being assessed.
Organon said pending claims and proceedings were not expected to be material in its opinion, though outcomes remain uncertain. It may have indemnification obligations to Merck, including a potential share of a €39 million Spanish competition fine concerning NuvaRing if upheld. The company has no insurance for most product-liability exposures. Its legal-defense reserve was $15 million at September 30, 2022.
Important facts for investors to verify
- Whether revenue growth excluding foreign exchange translates into sustained reported growth, given currency headwinds and product-level competitive pressures.
- Whether operating cash flow recovers as payables and other working-capital movements normalize.
- Debt repayment capacity, refinancing and variable-rate exposure, alongside the quarterly dividend and acquisition-related spending.
- Commercial progress and contingent milestone exposure for the Cirqle, Henlius and Daré agreements, as well as the expected 2023 U.S. Hadlima launch and Xaciato availability.
- Developments in product litigation, potential Merck indemnities, supply risks, COVID-related disruption and the eventual impact of U.S. tax legislation.